Investigational Therapy Gets Fast Track Status for Glioblastoma Multiforme
In preclinical studies, WP1122 has shown to increase cellular uptake of 2-DG, increase drug half-life, and increase the ability to cross the blood brain barrier.
Diagnosis & Disease Information
FDA Panel Votes Against Omburtamab Due to Multiple Efficacy Issues
Omburtamab is an investigational radiolabeled monoclonal antibody designed to target tumor cells that express B7-H3.
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
Vaccine Candidate Gets Orphan Drug Status for Glioblastoma Treatment
VBI-1901 is an investigational bivalent eVLP vaccine immunotherapeutic candidate designed to target 2 highly immunogenic CMV antigens, gB and pp65.
FDA Rejects Pedmark NDA Again Citing Manufacturing Deficiencies
The application could not be approved in its present form due to manufacturing deficiencies.
Medicinal Cannabis Improves Quality of Life for Patients With High-Grade Gliomas
A 1:1 ratio of THC to CBD proved superior to a 4:1 ratio.
- Loading...
Loading...
Loading... 
Loading...